Clinical Trial

Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Doctors leading this study would like to learn about providing cancer treatment/therapies to Nigerian women with breast cancer based on their human epidermal growth factor receptor 2 (HER2) status. This study will focus on the efficacy and safety of anti-HER2 cancer treatment before and after surgery.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2024-03-29; most recent amendment 2026-02-13.
Status change: Not Yet Recruiting → Recruiting 2026-02-13
Trial Details
NCT Number NCT06348134
Lead Sponsor University of Chicago
Conditions Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, HER2-positive Breast Cancer, Breast Cancer
Enrollment 74 participants
Start Date 2025-03-18
Primary Completion 2034-07-01 (estimated)
Study Completion 2036-07-01 (estimated)
Updated on ClinicalTrials.gov 2026-02-17